Your browser doesn't support javascript.
loading
[Analysis on post-marketing effectiveness and immunogenicity of enterovirus-A71 vaccine].
Hua, R J; Huang, J; Zhang, X J; Shen, Q; Cai, M Y; Yuan, F; Zhang, Y; Cui, P F; Li, Y; Shi, H Y; Xu, B.
Affiliation
  • Hua RJ; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China; Public Health of Fudan University, Shanghai 200032, China.
  • Huang J; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China.
  • Zhang XJ; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China.
  • Shen Q; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China.
  • Cai MY; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China.
  • Yuan F; Jing'an District Center for Disease Control and Prevention, Shanghai 200072, China.
  • Zhang Y; Institute of Medical Biology, Chinese Academy of Medical Science, Kunming 650106, China.
  • Cui PF; Institute of Medical Biology, Chinese Academy of Medical Science, Kunming 650106, China.
  • Li Y; Institute of Medical Biology, Chinese Academy of Medical Science, Kunming 650106, China.
  • Shi HY; Institute of Medical Biology, Chinese Academy of Medical Science, Kunming 650106, China.
  • Xu B; Public Health of Fudan University, Shanghai 200032, China.
Zhonghua Liu Xing Bing Xue Za Zhi ; 41(9): 1518-1521, 2020 Sep 10.
Article in Zh | MEDLINE | ID: mdl-33076610
ABSTRACT

Objective:

To analyze the effectiveness and immunogenicity of enterovirus-A71(EV-A71) vaccine in immunization program.

Methods:

A cohort study was conducted in immunization clinics in Jing'an district in Shanghai from October to December 2017. Children who received EV-A71 vaccine based on a 2-dose schedule (on day 0 and day 30) were enrolled as vaccine group and those who received no EV-A71 vaccine were enrolled as control group. After 1-year follow-up, the effectiveness and neutralizing antibody level and the positive results of antibody immunogenicity in vaccine group were analyzed.

Results:

A total of 3 018 children aged 8-20 months were enrolled, in whom 1 211 were in vaccine group and 1 807 were in control group. The vaccine effectiveness was 100% against EV-A71-associated hand, foot, and mouth disease (HFMD) indicated by 1 year follow-up (95%CI -66.99%-100.00%). The geometric mean titer of neutralizing antibody (GMT) was 41.76 (95%CI 35.60-49.34) at day 60 and 28.44(95%CI 23.59-34.54) at day 365 in 124 children in vaccine group.

Conclusions:

In children, EV-A71 vaccine elicited EV-A71-specific immune response. Less EV-A71-associated HFMD cases have been observed, further observation is needed.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Enterovirus / Hand, Foot and Mouth Disease Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans / Infant Country/Region as subject: Asia Language: Zh Journal: Zhonghua Liu Xing Bing Xue Za Zhi Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Enterovirus / Hand, Foot and Mouth Disease Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans / Infant Country/Region as subject: Asia Language: Zh Journal: Zhonghua Liu Xing Bing Xue Za Zhi Year: 2020 Document type: Article